Scienmag

MAY 26, 2022

— CRISPR has ushered in the era of genomic medicine. A line of powerful tools has been developed from the popular CRISPR-Cas9 to cure genetic diseases. ITHACA, N.Y.

Gene Editing 63

Gene Editing Genetic Disease Gene Genome 63

pharmaphorum

AUGUST 24, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that could be worth up to $1.2 The post Vertex builds in gene editing yet again, with $1.2bn Arbor deal appeared first on.

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

Scienmag

APRIL 21, 2021

New approach to gene therapy can correct any disease-causing mutation within a gene UNIVERSITY PARK, Pa.

Gene 52

Gene Gene Editing Gene Therapy Genetic Disease 52

pharmaphorum

JANUARY 10, 2022

The company has also stated, at the same time as the study was announced, that it will look at developing mRNA technology in oncology and genetic diseases. Similar to Pfizer, Sanofi noted that bringing the companies into its portfolio would allow it to leverage research capabilities in oncology and inflammatory disease.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

pharmaphorum

FEBRUARY 17, 2022

Oxbryta is the first medicine approved in Europe that directly prevents sickle haemoglobin (HbS) polymerisation, the molecular basis of sickling and destruction of red blood cells in SCD, and has been tipped to become a $1 billion-plus blockbuster at peak.

Drugs 59

Drugs Gene Therapy Gene Editing Gene 59

The Pharma Data

DECEMBER 13, 2020

“Our company and R&D portfolio are entering into an exciting phase, as evidenced by the recent close of Series B financing and submission of the first gene editing product IND in China,” said Dong Wei, Ph.D.?CEO

Business Development 40

Business Development Development Gene Editing In-Vivo 40

XTalks

DECEMBER 22, 2021

The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. RNA-based treatments include RNA interference (RNAi) with double-stranded RNA molecules, or small interfering RNA (siRNA) involving single-stranded antisense oligonucleotides (ASOs).

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

DECEMBER 29, 2022

In 2023, a number of gene therapies are expected to get the FDA green light. This includes the first ever CRISPR gene editing therapy from Vertex and CRISPR therapeutics for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

JANUARY 6, 2025

Whether its the integration of nanotechnology in medicine, the evolution of point-of-care (POC) diagnostics or the transformative impact of CRISPR and regenerative medicine, these biotech trends are pushing scientific boundaries and creating new opportunities for businesses and researchers alike. billion by 2032, with a CAGR of 10.1

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111